Treatment of vivax malaria with sulfadoxine-pyrimethamine and with pyrimethamine alone
โ Scribed by E.B. Doberstyn; C. Teerakiartkamjorn; R.G. Andre; P. Phintuyothin; S. Noeypatimanondh
- Publisher
- Elsevier Science
- Year
- 1979
- Tongue
- English
- Weight
- 264 KB
- Volume
- 73
- Category
- Article
- ISSN
- 0035-9203
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Artemisinin derivatives, such as artesunate, have a short half-life and very rapid anti-malarial activity. Theoretically, using such agents in conjunction with well-established anti-malarial drugs such as sulfadoxine-pyrimethamine may reduce the rate of drug resistance. Such a combination has not pr
fluorochrome-labelled nucleotides (Isola et al., 1994), such that all chromosomes can be included in the analysis. This novel approach combines screening for aneuploidy by CGH with precise mapping and sampling of the term placenta, separation of the placental cell lineages, and quantification of mo
Chloroquine can no longer be recommended as the first-line treatment for falciparum malaria in several parts of Africa, given the increasing resistance of Plasmodium falcipanrm to this drug. The sulfadoxinepyrimethamine combination (SP) is obviously an alternative candidate, that has already been se
A randomized 14-day study in vivo compared the response of Plasmodium falciparum malaria to amodiaquine (35 mg/kg) and sulfadoxine-pyrimethamine (sulfadoxine, 25 mg/kg) in symptomatic outpatients at 2 sites in northern and western Kenya during 1993. Of the 239 patients recruited, 181 (76%) completed